Search

The integration of deep learning into clinical decision infrastructure represents a pivotal advancement in healthcare systems and analytics, transforming disparate data streams into actionable intelligence that supports real-time, evidence-based decision-making. This narrative review synthesizes peer-reviewed literature to examine the systems-oriented implications of deep learning deployment within healthcare ecosystems. We focus on the architectural interplay among data ingestion, model inference, and decision-support loops, emphasizing how these elements enable closed-loop systems that adapt to evolving clinical contexts.Deep learning’s capacity to process multimodal data—encompassing electronic health records (EHRs), medical imaging, and real-time monitoring—has enabled sophisticated analytics frameworks that enhance diagnostic accuracy, prognostic modeling, and therapeutic optimization. For instance, fusion techniques combining imaging with structured EHR data have demonstrated potential for precision health applications, enabling nuanced patient stratification and personalized interventions. In mental health, deep learning models applied to outcome research have revealed patterns in longitudinal data, informing system-wide analytics that bridge predictive modeling with clinical workflows.From a systems perspective, the review highlights the evolution of clinical decision support systems (CDSS) augmented by deep learning, which incorporate feedback mechanisms to refine model performance and mitigate risks such as bias amplification. Ethical considerations, including algorithmic fairness and transparency, are integral to sustainable integration, as underscored by guidelines for early-stage evaluation and reporting standards. We explore architectures that facilitate human-AI collaboration, where deep learning serves as an augmentative tool rather than a replacement, ensuring alignment with clinical governance.Challenges in scalability, such as interoperability across healthcare infrastructures and the need for reproducible machine learning pipelines, are critically analyzed through a lens of systems resilience. The synthesis reveals opportunities for closed-loop systems that iteratively learn from interventions, promoting adaptive healthcare delivery. Ultimately, this review posits that deep learning’s role in clinical decision infrastructure hinges on holistic systems design that balances technological innovation with clinical utility and equity. By providing an original interpretive framework, we delineate pathways for integrating deep learning into healthcare analytics and advocate for governance models that prioritize patient-centered outcomes.

Breast cancer remains a leading cause of cancer-related mortality among women worldwide, underscoring the importance of effective screening strategies for early detection and improved survival. Although conventional modalities such as mammography reduce mortality, they are limited by false positives, false negatives, and overdiagnosis, particularly in dense breast tissue and diverse populations. Deep learning, especially convolutional neural networks (CNNs), has shown promise in improving diagnostic accuracy and reducing inter-reader variability; however, its translation into routine clinical practice requires critical evaluation beyond reported performance metrics. This critical review evaluates CNN-based deep learning applications for breast cancer detection across mammography, ultrasound, and MRI, with emphasis on training strategies and barriers to clinical deployment. A targeted literature search identified peer-reviewed studies focusing on CNN architectures, transfer learning, and implementation challenges. Findings indicate that models such as ResNet, DenseNet, and EfficientNet perform well in controlled settings, supported by transfer learning and data augmentation approaches. However, these results often fail to translate into consistent clinical performance, particularly across imaging modalities and real-world workflows. Limitations including demographic bias, insufficient external validation, and weak evidence of outcome or cost-effectiveness highlight a substantial gap between experimental success and clinical readiness. The review concludes that while deep learning in breast imaging is promising, its adoption should remain cautious and evidence-driven until robust clinical benefit is clearly demonstrated.

Oncology drug development is an expensive and high-failure process, with costs exceeding two billion dollars per approved drug and success rates below 10%. Deep learning has recently been explored as a strategy to improve efficiency across the drug discovery pipeline. This systematic review evaluates its application in target identification, compound screening and de novo drug design, and clinical trial optimization. Following PRISMA 2020 guidelines, multiple databases were searched and studies were screened using predefined inclusion criteria, with risk of bias assessed via established tools. The literature shows that graph neural networks and transformer-based models are the most widely used architectures, particularly in early-stage discovery tasks. Although many studies report strong in silico performance, often with AUC values above 0.80, only a small proportion demonstrate experimental or clinical validation. Overall, deep learning significantly advances computational drug discovery in oncology, but translation into clinically validated therapies remains limited, especially in trial optimization, highlighting the need for stronger prospective and experimental validation frameworks.

Sleep disorders, including obstructive sleep apnea, insomnia, restless legs syndrome, narcolepsy, and central sleep apnea, represent a major public health burden. Polysomnography is the diagnostic gold standard but is resource-intensive, leading to increasing use of home sleep apnea testing and wearable devices to improve accessibility. This systematic review evaluates deep learning models in sleep medicine across polysomnography, home sleep apnea testing, and wearable data, focusing on architectures, signal types, validation approaches, diagnostic tasks, and clinical readiness. A PRISMA 2020–compliant search was conducted in PubMed, IEEE Xplore, Scopus, and Web of Science for studies published from 2017 to 2025, including those applying deep learning for sleep staging, apnea/hypopnea detection, or sleep disorder diagnosis using PSG, HSAT, or wearable-derived signals. Twenty-nine studies were included. Convolutional neural networks were the most widely used architecture, often combined with recurrent or hybrid models for temporal dependencies, while transformer-based models have recently emerged for long-sequence sleep analysis. Deep learning methods demonstrate strong performance in sleep staging and respiratory event detection, especially using polysomnography data. However, limited external validation, heterogeneous datasets, and a lack of prospective clinical deployment remain major barriers to clinical translation.